BRIEF—ICER to assess treatments for spinal muscular atrophy
US health technology assessor the Institute for Clinical and Economic Review (ICER) announced today that it will assess the comparative clinical effectiveness and value of apitegromab (from Scholar Rock) for the treatment of spinal muscular atrophy (SMA).
The ICER will also assess new evidence (since ICER’s 2019 Final Evidence Report) on the clinical effectiveness of nusinersen (Spinraza, from Biogen) and onasemnogene abeparvovec-xioi (Zolgensma, from Novartis), as well as the evidence for risdiplam (Evrysdi, from Genentech). Risdiplam was not evaluated in the 2019 report.
The assessment will be publicly discussed during a meeting of the Midwest CEPAC in August 2025, where the independent evidence review panel will deliberate and vote on evidence presented in the ICER’s report.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze